Core Viewpoint - Algernon Health Inc. is conducting a non-brokered private placement to raise gross proceeds of $500,000 through the issuance of units priced at $0.07 each, aimed at advancing its Alzheimer's Disease program and other operational needs [1][5]. Group 1: Offering Details - The offering consists of units, each comprising one Class A common share and one-half common share purchase warrant, with a full warrant allowing the purchase of one common share at an exercise price of $0.15 for 12 months [2]. - The exercise price of the common warrants will increase to $0.25 after the first anniversary and to $0.50 after the second anniversary of the issuance date [2][3]. - The offering is expected to close in tranches by November 30, 2025, with potential cash finder's fees of up to 8% of the proceeds [4]. Group 2: Use of Proceeds - Proceeds from the offering will be utilized to advance the company's Alzheimer's Disease program, cover general and administrative expenses, and for working capital purposes [5]. Group 3: Share Structure and Securities - The company has converted 1,268,334 subscription receipts into Series 1 preferred shares and issued additional preferred shares and warrants related to previous placements and acquisitions [7]. - The Series 1 preferred shares carry a 10% annual dividend and are convertible into ten Class A common shares, with voting rights [9]. Group 4: Company Overview - Algernon Health focuses on brain-specific PET scanning services for early-stage detection of Alzheimer's and other neurological conditions, and is advancing a psychedelic program for recovery from stroke and traumatic brain injury [10].

Core Points - Algernon Pharmaceuticals Inc. held its annual and special meeting of shareholders, where a resolution to alter the company's authorized share structure to include an unlimited number of Preferred Shares was approved with over 93% of votes in favor [1] - The Series 1 Preferred Shares will offer a ten percent annual dividend and are convertible into ten Common Shares without payment [2] - The company plans to issue a total of 450,000 Preferred Shares and 450,000 Preferred Warrants related to a recent acquisition, along with 1,268,334 Preferred Shares and 634,167 Preferred Warrants from a private placement [2] - All five nominees for the board of directors were elected with over 95% of votes in favor [3] - The company intends to change its name to Algernon Health Inc. to reflect its focus on Alzheimer's Disease diagnostics and plans to establish specialized neuroimaging clinics across North America [4] Company Overview - Algernon Pharmaceuticals is focused on brain-specific PET scanning services for detecting Alzheimer's disease and other neurological conditions, and is also advancing a psychedelic program for stroke and traumatic brain injury [5] - The company holds a 20% equity position in Seyltx, a U.S.-based drug development company working on a chronic cough drug called Ifenprodil [5]